New York State Common Retirement Fund purchased a new position in shares of Surface Oncology, Inc. (NASDAQ:SURF) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,500 shares of the company’s stock, valued at approximately $213,000. New York State Common Retirement Fund owned approximately 0.07% of Surface Oncology as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Captrust Financial Advisors lifted its stake in Surface Oncology by 4,700.0% during the first quarter. Captrust Financial Advisors now owns 4,800 shares of the company’s stock worth $37,000 after purchasing an additional 4,700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Surface Oncology during the first quarter worth $48,000. Novare Capital Management LLC acquired a new position in Surface Oncology during the first quarter worth $78,000. Hilltop Holdings Inc. acquired a new position in Surface Oncology during the first quarter worth $79,000. Finally, Kestra Private Wealth Services LLC acquired a new position in Surface Oncology during the first quarter worth $80,000. Institutional investors own 49.77% of the company’s stock.
A number of research analysts have commented on the company. Jonestrading restated a “buy” rating and set a $18.00 price target on shares of Surface Oncology in a research note on Friday, June 4th. Zacks Investment Research lowered Surface Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, August 7th. Finally, BTIG Research reaffirmed a “buy” rating and set a $17.00 price objective on shares of Surface Oncology in a research report on Sunday. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $14.80.
Surface Oncology (NASDAQ:SURF) last issued its quarterly earnings data on Thursday, August 5th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.13). The business had revenue of $0.52 million during the quarter. As a group, research analysts predict that Surface Oncology, Inc. will post -1.24 EPS for the current year.
Surface Oncology Profile
Surface Oncology, Inc operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells.
Further Reading: Average Daily Trade Volume Explained
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.